secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001193125-26-126244
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero posts Q4 net income $31.5M; tebipenem HBr PDUFA set for June 18, 2026
---------------------------------------------------------------------------

- Q4 2025 net income $31.5M (vs $20.9M loss); diluted EPS $0.53.
- Full year 2025 net income $8.6M (vs $68.6M loss); diluted EPS $0.15.
- Total revenue Q4 $41.3M (vs $15.0M); full year $66.8M (vs $48.0M).
- Tebipenem HBr NDA resubmitted; FDA PDUFA date June 18, 2026, per partner GSK.
- Cash $40.3M sufficient into 2028; received $25M milestone from GSK in Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312526126244/0001193125-26-126244-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312526126244/d107475d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-126244

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer